Last reviewed · How we verify
V419
V419 is a small molecule that targets the SGLT2 receptor.
V419 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | V419 |
|---|---|
| Also known as | PR51, VAXELIS® |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Biologic |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, V419 reduces glucose reabsorption in the kidneys, lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
Key clinical trials
- Safety, Tolerability, and Immunogenicity of Vaxelis™ in Children Previously Vaccinated With Vaxelis™ or Hexyon™ (V419-016) (PHASE4)
- Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007) (PHASE3)
- Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008) (PHASE3)
- Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011) (PHASE3)
- Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010) (PHASE3)
- A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006) (PHASE3)
- Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005) (PHASE3)
- A Study of the Safety and Tolerability of V419 in Healthy Infants at 2,4, 6 and 12 to 14 Months of Age (V419-003) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- V419 CI brief — competitive landscape report
- V419 updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI